Investigation of the efficacy and safety of a diindolylmethane-based drug in patients with cervical intraepithelial neoplasia grades 1-2 (CIN 1-2)


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Objective. To investigate the efficacy and safety of the vaginal suppositories Cervicon-DIM (diindolylmethane) in patients with histologically confirmed neoplastic processes of the cervix uteri - cervical intraepithelial neoplasia grades 1-2 (CIN 1-2). Subject and methods. The randomized study enrolled 160 patients aged 18 to 45 years; the follow-up period was 3 months. The investigators analyzed clinical and laboratory data and evaluated the efficacy and safety of treatment with Cervicon-DIM versus placebo. Results. Cervicon-DIM was shown to contribute to the elimination of human papillomavirus infection and to the regression of mild and moderate neoplastic processes of the cervix uteri (CIN 1-2). Conclusion. It is appropriate to prescribe Cervicon-DIM as one suppository (100 mg) twice daily for 3 months to patients with human papillomavirus infection and those with CIN 1-2.

全文:

受限制的访问

作者简介

Gennady Sukhikh

National Medical Research Center of Obstetrics, Gynecology, and Perinatology named after Academician V.I. Kulakov

Email: gtsukhikh@mail.ru
MD, PhD, Professor, Academician of Russian Academy of Sciences, Director

Lev Ashrafyan

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: levaa2004@yahoo.com
MD, Academician of RAS, Professor, Director of the Institute of Oncogynecology and Mammology

Vsevolod Kiselev

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: vkis10@mail.ru
doctor of biological sciences, Deputy Director for Science, Head of the laboratory of epigenetics of the Institute of Oncogynecology and Mammology

Inna Apolikhina

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University

MD, Professor of the Department of Obstetrics, Gynecology, Perinatology and Reproductology, I.M. Sechenov First Moscow State Medical University, a doctor of the highest category, head of the Department of Aesthetic Gynecology and Rehabilitation and a day hospital

Larisa Maltseva

Kazan State Medical Academy

Email: laramalc@mail.ru
MD, professor, head of the Obstetrics and Gynecology Department № 1

Larisa Suturina

Research Center for Family Health and Human Reproduction Problems, Siberian Branch, Russian Academy of Medical Sciences

Email: lsuturina@mail.ru
MD, Professor of the Department of Endocrinology

Sergey Selivanov

Siberian State Medical University, Ministry of Health of Russia

Email: health@ldc.tom.ru
MD, assistant of the Department of Urology

T. Leonidova

Ministry of Health of the Perm Territory

Email: drleonidova@mail.ru
MD, doctor of the highest category, gynecologist-endocrinologist, chief oncogynecologist of the Ministry of Health of the Perm Krai.

Vitaly Tskhai

V.F. Voino-Yasenetsky Krasnoyarsk State Medical University

Email: tchai@yandex.ru
MD., prof., Head of Department of Perinatology, Obstetrics and Gynecology, Medical Faculty

Viktor Radzinsky

Peoples' Friendship University of Russia

Email: radzinsky@mail.ru
Doctor of Medicine, professor, Honored Researcher of the Russian Federation, corresponding member of the Russian Academy of Sciences, vicepresident of the Russian Society of Obstetricians and Gynecologists; Head of the Department of Obstetrics and Gynecology with a Perinatology Course of the Medical Institute

Irina Ordiyants

Peoples’ Friendship University of Russia

Email: ordiyantc@mail.ru
Professor of the Department of Obstetrics and Gynecology with the course of Perinatology

Tamara Bebneva

Peoples' Friendship University of Russia

Email: bebn@mail.ru
Candidate of Medical Sciences, Associate Professor of the Department of Obstetrics, Gynecology and Reproductive Medicine, Faculty of Advanced Training for Medical Professionals

I. Evtushenko

Siberian State Medical University, Ministry of Health of Russia

Email: evtushenko_id@mail.ru
MD, professor, head of Department of Obstetrics and Gynecology

V. Udut

E.D. Goldberg Research Institute of Pharmacology and Regenerative Medicine

Email: udutv@mail.ru
MD, Professor, Corresponding Member of RAS, Deputy director for scientific and medical work, head of the laboratory of physiology, molecular and clinical pharmacology E.D. Goldberg NIIFiRM.

N. Kulagina

I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia

Email: dr.kulagina@mail.ru
MD, Professor of the Department of Obstetrics and Gynecology

A. Baranov

Northern State Medical University

Email: albar@atnet.ru
Doctor of Medicine, Head of Department of Obstetrics and Gynecology

R. Khasanov

Kazan State Medical Academy

Email: kgma.rf@tatar.ru
MD, Corresponding Member of RAS, Professor, Director of Kazan State Medical Academy, Head of the Department of Oncology, Radiology and Palliative Medicine, Honored Doctor of the Russian Federation and the Republic of Tatarstan, Chief Oncologist of the Privolzhsky Federal District and the Republic of Tatarstan.

V. Guryeva

Territorial Consultative Polyclinic, Territorial Clinical Hospital, Barnaul

Email: ag.fpk@mail.ru
MD, Professor, Honored Doctor of the Russian Federation, full member of the Russian Academy of Natural Sciences, twice winner of the Altai Territory Award in the region. science and technology.

I. Shamina

Omsk State Medical University, Ministry of Health of Russia

Email: innadocsever@rambler.ru
Ph.D., Associate Professor of the Department of Obstetrics and Gynecology No. 2

Lyudmila Karakhalis

Kuban State Medical University

Email: lomela@mail.ru
Doctor of Medicine, Professor of the Department of Obstetrics, Gynecology, and Perinatology

E. Muyzhnek

AO MiraxBioFarma

Email: MuyzhnekEL@ilmixgroup.ru
Ph.D., Director for Science

参考

  1. Workowski K.A., Bolan G.A.; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm. Rep. 2015; 64(RR-03): 1-137.
  2. WHO Guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. Geneva: World Health Organization; 2013.
  3. Banerjee S., Kong D., Wang Z., Bao B., Hillman G.G., Sarkar F.H. Attenuation of multi-targeted proliferation-linked signaling by 3,3'-diindolylmethane (DIM): from bench to clinic. Mutat. Res. 2011; 728(1-2): 47-66.
  4. Sepkovic D.W., Stein J., Carlisle A.D., Ksieski H.B., Auborn K., Bradlow H.L. Diindolylmethane inhibits cervical dysplasia, alters estrogen metabolism, and enhances immune response in the K14-HPV16 transgenic mouse model. Cancer Epidemiol. Biomarkers Prev. 2009; 18(11): 2957-64.
  5. Del Priore G., Gudipudi D.K., Montemarano N., Restivo A.M., Malanowska-Stega J., Arslan A.A. Oral diindolylmethane (DIM): pilot evaluation of a nonsurgical treatment for cervical dysplasia. Gynecol. Oncol. 2010; 116(3): 464-7.
  6. Zhu J., Li Y., Guan C., Chen Z. Anti-proliferative and pro-apoptotic effects of 3,3'-diindolylmethane in human cervical cancer cells. Oncol. Rep. 2012; 28(3): 1063-8.
  7. Ashrafian L., Sukhikh G., Kiselev V., Paltsev M., Drukh V., Kuznetsov I., Muyzhnek E., Apolikhina I., Andrianova E. Double-blind randomized placebocontrolled multicenter clinical trial (phase IIa) on diindolylmethane’s efficacy and safety in the treatment of CIN: implications for cervical cancer prevention. EPMA J. 2015; 6: 25.
  8. Landy R., Pesola F., Castanon A., Sasieni P. Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case-control study. Br. J. Cancer. 2016; 115(9): 1140-6.
  9. Massad L.S., Einstein M.H., Huh W.K., Katki H.A., Kinney W.K., Schiffman M. et al.; 2012 AS CCP Consensus Guidelines Conference. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet. Gynecol. 2013; 121(4): 829-46.
  10. Kyrgiou M., Mitra A., Arbyn M., Stasinou S.M., Martin-Hirsch P., Bennett P., Paraskevaidis E. Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis. BMJ. 2014; 349: g6192.
  11. Kyrgiou M., Mitra A., Arbyn M., Paraskevaidi M., Athanasiou A., Martin-Hirsch P.P. et al. Fertility and early pregnancy outcomes after conservative treatment for cervical intraepithelial neoplasia. Cochrane Database Syst. Rev. 2015; (9): CD008478.
  12. Kyrgiou M., Athanasiou A., Paraskevaidi M., Mitra A., Kalliala I., Martin-Hirsch P. et al. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and metaanalysis. BMJ. 2016; 354: i3633.
  13. Kyrgiou M., Athanasiou A., Kalliala I.E.J., Paraskevaidi M., Mitra A., Martin-Hirsch P.P. et al. Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease. Cochrane Database Syst. Rev. 2017; (11): CD012847.34.
  14. Cytological changes in the cervix, vagina and vulva (online). Helsinki: Finnish Medical Society Duodecim; 2016. Available at: www.kaypahoito.fi Accessed 21.11. 2016.
  15. Moscicki A.B., Ma Y., Wibbelsman C., Darragh T.M., Powers A., Farhat S., Shiboski S. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet. Gynecol. 2010; 116(6): 1373-80.
  16. Castle P.E., Schiffman M., Wheeler C.M., Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet. Gynecol. 2009; 113(1): 18-25.
  17. Dalessandri K.M., Firestone G.L., Fitch M.D., Bradlow H.L., Bjeldanes L.F. Pilot study: effect of 3,3'-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. Nutr. Cancer. 2004; 50(2): 161-7.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2018